The news: Audi has just launched a new EV brand in China, and the company is making a bold branding move to set the vehicles ...

GSK has claimed a new approval for its respiratory syncytial virus (RSV) vaccine Arexvy, currently locked in a battle for market share with rival shots from Pfizer and Moderna, that could lend it ...

The arrangement will run for three years in the first instance and, according to GSK, also “supports potential future co-development and commercialisation of Arexvy […] for adults 60 years and ...

GlaxoSmithKline (GSK) has received approval for its vaccine, AREXVY, in Canada to prevent lower ... advice on which you ...

The newly approved vaccine, known as Arexvy, represents an advance in preventive health measures, addressing a significant adult demographic at risk from RSV complications. With this approval, Canada ...

US clinical-stage drug developer Acumen Pharmaceuticals (Nasdaq: ABOS) has appointed Amy Schacterle as chief regulatory officer and head of quality, reporting to Jim Doherty, president and chief ...

Unger: What's the background on lowering the age to 50 ... one by Pfizer called ABRYSVO that does not contain an adjuvant, and one by GSK called AREXVY that does. And the third RSV vaccine is by ...

Teva Pharmaceutical Industries Ltd. ADR-2.23% $19.91B ...

Results from the ARC-10 Phase III study of Arcus Biosciences (NYSE: RCUS) and Gilead Sciences’ (Nasdaq: GILD) domvanalimab and zimberelimab combination therapy indicate a significant reduction in ...

Per the seller, the Lexus V8 and six-speed stick make the home-built a street-legal race car.

IPC Indice de Precios Y Cotizaciones 51,449.43-395.74-0.76% ...